The Latest

Please join us for RegenMed, Inc. Investors Webinar, Monday, December 16 at 6:30 PM, New York time .RegenMed's CEO Michael P Tierney will review the Company's momentum through the end of the year, as well as expectations for 2025.For more information, see our Investors Page.

RegenMed Webinar: Michael P. Tierney, CEO and Co-Founder, Discusses The Company’s Investment Theses RegenMed is an established, revenue-producing company disrupting a + $1 trillion healthcare data market. Our November 12 webinar discussed the foundational elements which have led to its global client base, strong monthly recurring revenue growth, competitive moats, and plans for accelerated market capture. A total of ten self-contained segments from that webinar can be viewed on the Company’s Investors Page. The first three can be viewed below. The remainder will be published in subsequent Campaign Updates. THE FOUNDING OF A “ZERO-TO- ONE” COMPANY REAL WORLD HEALTHCARE DATA: THE RAW MATERIAL OF A + $1 TRILLION MARKET THE VALUABLE FINAL PRODUCT: REAL-WORLD EVIDENCE Invest today in a company with a proven product market fit, growing recurring revenues, competitive moats, and seasoned leadership which is disrupting a + $1 trillion market.

RegenMed was founded – and operates – on a fundamental financial principle: the most valuable company is that which can establish and then grow recurring revenues across a diverse client base. It is thus distinctive from many other forms of healthcare investments.The Challenges For Pre-Revenue Healthcare CompaniesHealthcare is obviously an enormous market – in the United States alone, it represents fully 17% of the country’s GDP. 1There are therefore thousands of investment opportunities, both with established and newer companies. Many of the latter tend to be bets on new products with any revenues far into the future. While some of these bets pay off, the great majority do not.Unfortunately, it is very difficult even for the largest drug companies to predict which of their clinical trials will prove successful. On average, 14% of drugs and vaccines that enter clinical trials receive regulatory approval. (Only 2% for oncology drugs.)The Financial ConsequencesOnly the best capitalized companies can withstand the financial implications of this reality. In 2023, biotech bankruptcies reached a 10-year high, with more companies filing for bankruptcy than any year since 2010. This trend continued into 2024, with 22 biotech companies shutting down. 2 Indeed, the broader healthcare industry also saw a surge in bankruptcies. In 2023, 79 healthcare companies with liabilities of at least $10 million filed for bankruptcy, more than triple the number in 2021. 3 In 2023, 17 out of 80 healthcare bankruptcies (21%) involved private equity-backed firms, marking a 112.5% increase over the past five years. 4How RegenMed Is DifferentRegenMed is selling shovels to gold miners – its patented product Circles is needed by any medical provider or product manufacturer which needs to conduct a clinical study. (As discussed in an earlier post, RegenMed also participates with its clients in the monetization of those studies.) RegenMed has established a strong product-market fit, with revenues earned from a broad variety of clients in North America, Europe and elsewhere. Those revenues are recurring and growing – the company’s business model is predicated on monthly subscriptions and small per Case charges. This low pricing is an important competitive moat in today’s far-too-expensive healthcare world. It also allows rapid scaling. RegenMed is led by an experienced management team with proven track records. They know that “slow and steady” wins the race. They focus on cash earnings, minimizing debt, and continuing to scale the Company’s established product-market fit in its large addressable markets.

Strong Demand For ShovelsEvery drug, biologic and medical device company needs to conduct at least one clinical trial before it is allowed to market its product. Increasingly, most also need to collect long-term outcomes through “post-market surveillance”. As of April 15, 2024, there were over 491,000 clinical studies registered worldwide.1 This does not include the many thousands of other studies in medical fields conducted by research organizations, medical societies, and academic medical centers.Each of those studies requires data collection tools to capture, aggregate, report and analyze clinical and outcomes information. As value-based care and real-world evidence become more important in healthcare, the need for these tools will greatly expand. RegenMed’s Circles deliver to individual physicians -- as well as to sophisticated industry clients – a regulatorily compliant, low cost, and highly efficient platform for any type of clinical study.‍Plus, A Piece Of The GoldmineCritically, each Circle can generate a clinically and statistically significant dataset proprietary to Circle Members and to RegenMed. (See here for more details.) Such datasets represent significant and ongoing value for many potential healthcare constituencies. RegenMed is not only selling shovels to the healthcare data gold miners, it is also helping them monetize their efforts while participating in that monetization.‍

Fewer than half of Americans feel that the healthcare system is good enough. (Over 20% rate it as poor.) A large percentage of doctors question the healthcare system's effectiveness in meeting patients’ needs. Almost half of physicians report burnout -- emotional exhaustion, depersonalization, reduced sense of personal accomplishment. And as indicated, these trends are only worsening. RegenMed’s business model is firmly rooted in the primacy of healthcare professionals. It is they who – by virtue of education, experience and disposition -- are able to diagnose, treat, and engage with patients in a meaningful way. It is they who can identify the most important clinical issues, the most sensible and cost-effective approach to addressing those issues, and the areas where new products and treatment protocols will have the broadest impact. RegenMed’s Circles – especially its Physician-Owned Circles – empower the clinical independence of any healthcare professional. They do not interrupt normal clinical flow, but make it more meaningful for both clinicians and patients. And, critically, they return to physicians a large amount of the financial value which they deserve. There are over 1 million active physicians in the U.S., and almost 2 million in the European Union. Very few of them do not want to exercise their best clinical judgment on behalf of their patients. Very few of them do not want the tools, data, and ethical financial incentive which will allow them to do so. RegenMed’s strong monthly growth only confirms this strong demand among physicians all over the world. We are confident that this is only the beginning of “zero to one” business model which can have a profound and beneficial impact on healthcare.